arrow
N

Neus Llarch

bclc group and institut d'investigacions biomediques august pi i sunyer
H指数:11
被引数:797

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Erratum to ‘BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update’ [J Hepatol (2026) 631–654]

勘误:‘BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update’ [J Hepatol (2026) 631–654]

2026-04-050
PRE
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

临床试验:二线治疗中,在瑞戈非尼基础上早期加用纳武利尤单抗治疗肝细胞癌患者(GOING试验)

2026-02-230
OAAI
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma

血清降钙素原: 诊断和监测纤维板层肝癌的新型肿瘤生物标志物

2026-02-060
PRE
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

2025-10-270
PRE
Corrigendum to” Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes,” [Eur J Cancer 2025 May 15:221:115404.]

勘误:“接受免疫治疗的肝细胞癌患者的心血管不良事件:合并症和临床结局的影响”,[Eur J Cancer 2025 May 15:221:115404.]

2025-06-120
PRE
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes

接受免疫治疗的原发性肝癌患者的心脏不良事件:合并症和临床结局的影响

2025-05-010
PRE
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
2022-04-0121
PRE
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

2021-07-061
OAAI